Carla A. Frederick MD
Carla A. Frederick
MD
Clinical Assistant Professor
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Pulmonary & Critical Care Medicine
Professional Summary:
My clinical practice focuses on management of general pulmonary disease with a specialized interest in cystic fibrosis (CF) and bronchiectasis.
As a physician-consultant for the inpatient UBMD pulmonary consult services at Buffalo General Medical Center (BGMC) and at Roswell Park Cancer Institute, I attend to the needs of hospitalized patients with pulmonary problems in conjunction with the UBMD pulmonary team. This talented inpatient consult team of fellows, residents and medical students works under my supervision, and through my mentoring and teaching of them I hope to share my expertise and give back to medical education by training future healthcare professionals.
I see patients to evaluate and treat pulmonary disorders such as shortness of breath, lung masses, abnormal chest imaging, abnormal pulmonary function tests, chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease and bronchiectasis. My outpatient office locations are the Heart and Lung Center at BGMC and the UBMD Specialty Clinic on Youngs Rd in Williamsville.
As the Adult Director of the Cystic Fibrosis Center in Buffalo, the only care facility in Western New York accredited by the national Cystic Fibrosis Foundation, I provide comprehensive care for individuals with cystic fibrosis with a specially devoted multidisciplinary team. I also provide local care for patients who have received lung transplants for cystic fibrosis, coordinating and collaborating on their care with the transplant physicians and health care providers.
In addition to these responsibilities as a pulmonologist, I attend to hospitalized patients at BGMC and WCHOB who are patients of the UBMD Internal Medicine and Pediatric practices to provide continuity of care for those physicians and their patients.
I am actively engaged in clinical research through many international clinical trials, and through this work strive for improved therapies and a cure for individuals with cystic fibrosis. I am excited to see the major advances made recently with genetic mutation specific therapy being delivered to individuals with CF. Research will continue to progress as a result of successful clinical trials made possible by generous patients and the concerted efforts our highly productive local research team and the Cystic Fibrosis Foundation.
Education and Training:
- Fellowship, Pulmonary Medicine, University at Buffalo (2011)
- Fellowship, Pulmonary Medicine, University of Alabama at Birmingham (2010)
- Residency, Internal Medicine & Pediatrics, University of Tennessee Health Science Center (2009)
- Residency, Internal Medicine & Pediatrics, University at Buffalo (2007)
- MD, University at Buffalo (2005)
- BA, Major: Biology; Minor: Chemistry,Sports Medicine, Case Western Reserve University, Magna Cum Laude (2001)
Employment:
- Adult Program Director, Lung & CF Center, Oshei Women & Children‘s Hospital of Buffalo Lung & CF Center (2012-present)
- Clinical Assistant Professor, Medicine, University at Buffalo
Awards and Honors:
- CF Excellence in Care Award (2016)
- Gold Humanism Honor Society (2014)
Research Expertise:
- Cystic Fibrosis: Director of Adult Cystic Fibrosis Center Co-Principal Investigator of Center for Therapeutic Drug Network at the Women & Children‘s Hospital of Buffalo
- New therapeutics in cystic fibrosis: Clinical care, clinical research, and translational research related to cystic fibrosis
Grants and Sponsored Research:
- January 2015–December 2018
TherapeuticS Development Center (TDC)
Cystic Fibrosis Foundation Therapeutics, Inc.
Role: Principal Investigator
$443,986 - August 2014–July 2018
Success with Therapies Research Consortium
Cystic Fibrosis Foundation
Role: Principal Investigator
$108,000 - January 2013–May 2015
AquADEKs-2 trial: a study of the effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in CF.
Cystic Fibrosis Foundation
Role: Co-Investigator - January 2013–July 2014
A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor Monotherapy and in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F50
Vertex Pharmaceuticals, Inc.
Role: Principal Investigator - January 2013–January 2014
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa
Gilead
Role: Principal Investigator - January 2010–January 2013
iCARE: I Change Expectations and Raise Adherence
Cystic Fibrosis Foundation/Genentech, Inc./Novartis Pharmaceuticals Corporation
Role: Co-Investigator - January 2011–December 2012
VX-770 Expanded Access Program (EAP).
Vertex Pharmaceuticals, Inc.
Role: Co-Investigator - –December 2012
Remnant Biological and Autopsy Specimens for Cystic Fibrosis Cell Line Development: New Reagents for Understanding and Overcoming the deltaF508 Mutation.
Cystic Fibrosis Foundation Therapeutics; UAB Center for Clinical and Translational Science
Role: Co-Investigator - –December 2012
G551D Observational Study (GOAL) Gastrointestinal pH sub-study.
Cystic Fibrosis Foundation
Role: Co-Investigator - January 2010–January 2012
An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis
Vertex Pharmaceuticals, Inc.
Role: Co-Investigator - –December 2011
Nasal Potential Difference (NPD) Measurements Remote Reading Services for Multi-Center Trial Entitled: Nasal Potential Studies Utilizing CFTR Modulators.
UAB Center for Clinical and Translational Science
Role: Co-Investigator - January 2015
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Lumacaftor in Combination with Ivacaftor in Subjects Aged 6 Years and Older with with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Vertex Pharmaceuticals
Role: Co-Principal Investigator
$113,215 - February 2012
G551D Observational Study (GOAL)
Cystic Fibrosis Foundation
Role: Principal Investigator - January 2012
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors.
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients
Role: Principal Investigator - January 2010
Microbiology of Cystic Fibrosis Sputum.
Cystic Fibrosis Foundation
Role: Co-Investigator - January 2010
A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX-809 Alone and in Combination with VX-770 in Subjects with Cystic Fibrosis, Homozyg
Vertex Pharmaceuticals
Role: Co-Investigator
Journal Articles:
- Jiang K, Poppenberg KE, Wong L, Chen Y, Borowitz DS, Goetz DM, Sheehan DW, Frederick CA, Tutino VM, Meng H, Jarvis JN. RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations. J Cyst Fibros. 2018.
- Fusco NM, Meaney CJ, Wells C, Frederick CA, Prescott WA. Vancomycin Versus Vancomycin Plus Rifampin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis. J Pediatr Pharmacol Ther. 2018; 23(2).
- Fusco NM, Francisconi R, Meaney CJ, Duman D, Frederick CA, Prescott WA. Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis. J Pediatric Infect Dis Soc. 2017; 6(3).
- Provost K, Frederick CA, Sethi S. Bacterial infection.. Acute Exacerbations of Pulmonary Diseases (ERS Monograph), European Respiratory Society. 2017.
- Frederick C, Frederick CA. Psychosocial Challenges/Transition to Adulthood. Pediatr Clin North Am. 2016; 63(4).
Abstracts:
- Goetz DM, Frederick CA, Cogswell A, Fries L, Roach C, Rand K, Pardee C, Borowitz DS, Smith BA. Developing and Sustaining a Model for Depression and Anxiety Screening. Pediatr Pulmonol. 2017; 52(S47).
- Frederick CA, Fries L, Cogswell A, Roach C, Goetz DM, Smith BA. Association of Depression and Adverse Health Outcomes and Trends Over Time in Individuals with CF. Pediatr Pulmonol. 2017; 52(S47).
- Fusco NM, Francisconi R, Meaney CJ, Duman D, Frederick CA, Prescott WA Jr.. Association of vancomycin trough concentration with response to treatment for acute pulmonary exacerbation of cystic fibrosis. J Pediatr Pharmacol Ther. 2017; 22(2).
- Singh S, Frederick CA, Borowitz DS. Using Video Conferencing for Parent and Patient Advisory Group in Era of Infection Control. Pediatr Pulmonol. 2015; 50(S41).
- Goetz DM, Frederick CA, Roach CM, Cogswell A, Smith BA. The Relationship Between Depression and Patient Outcomes in Children and Adults with CF. Pediatr Pulmonol. 2015; 50(S41).
- Prentice S, Goetz DM, Flattery-Walsh L, Frederick CA. Annual Assessment of Vest Fitting and Condition in Patients Using High-Frequency Chest Wall Oscillation for Airway Clearance. Pediatr Pulmonol. 2014; 49(S38).
- Frederick CA, Goetz DM, Borowitz DS, Surace B. Patient and Family Perceptions of the New Infection Prevention and Control Guidelines. Pediatr Pulmonol. 2014; 49(S38).
- Gelfond D, Borowitz DS, Frederick CA, Uluer A, Sicilian L, Konstan MW, Rowe SM. Impact of Ivacaftor Therapy on the Intestinal pH Profile in CF Subjects with the G551D Mutation. Pediatr Pulmonol. 2013; 48(S36).
- Coburm-Miller C, Frederick CA, Borowitz DS. Using the New Vitamin D Recommendations to Improve Vitamin D Status in Patients with CF. Pediatr Pulmonol. 2012; 47(S35).
- Frederick CA, Valvo LE, Borowitz DS. Assessing Parent Readiness for Transition from a Pediatric to an Adult CF Program. Pediatr Pulmonol. 2012; 47(S35).
Evaluative Studies and Case Reports:
- Penmatsa H, Frederick CA, Nekkalapu S, Conoley VG, Zhang W, Li C, Kappes J, Stokes DC, Naren AP. Molecular characterization of S1118F-CFTR: A Mutation Associated with Meconium Ileus, Pancreatic Sufficiency, and Intermediate Sweat Chloride Levels. Pediatr Pulmonol. 2009; 44(10).
Professional Memberships:
- American Thoracic Society (2009–present)
- American College of Chest Physicians (2009–present)
- Christian Medical and Dental Association (2001–present)
Presentations:
- "Connection the Worlds of Medicine and Pharmacy to Effectively Treat this Disease" WNY Society of Health-System Pharmacists Continuing Education Cystic Fibrosis (2017)
- "Evaluation and Management of Incidental Pulmonary Nodules" UBMD Primary Care Update, UBMD (2017)
- "Opening Conversations About Sustaining Daily CF Care" North American Cystic Fibrosis Conference (2016)
- "Successful Strategies for Screening for Depression in CF" Memphis Family Day, University of Tennessee Health Science Center (2016)
- "Opening Conversations About Sustaining Daily CF Care Workshop Presentation" North American Cystic Fibrosis Conference (2016)
- "Adult Patient with Accelerated Pulmonary Decline" North American Cystic Fibrosis Conference, Cystic Fibrosis Foundation, Caregivers Session (2014)
- "Bronchitis and Bronchiectasis" UBMD Primary Care Update, UBMD (2014)
- "Physician Grand Rounds" North American Cystic Fibrosis Conference, Cystic Fibrosis Foundation (2013)
Service Activities:
- CFF Peer Mentoring Champion; Member (2017–present)
- ATS Transition Consortium Co-Chair; Co-Chair (2016–present)
- CF Expert Panel Co-Chair; Co-Chair (2016–present)
- Partnerships for Sustaining Daily Care Communications Intitiative National CFF; Member (2015–present)
- Adult Guide - Online Cystic Fibrosis Resource; www.cff.org/adults Adults with CF can seek information from an accredited website with helpful resources regarding different topics related to life as an adult with CF.; Editor (2012–present)